---
title: What to Know About Anal Sac Carcinoma
description: Discover key information about anal sac carcinoma in dogs, including symptoms, treatment options, and prognosis.
image: https://blog.fidocure.com/hubfs/Blog_AnalSacCarcinoma.png
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
# What to Know About Anal Sac Carcinoma
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/what-to-know-about-anal-sac-carcinoma) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/what-to-know-about-anal-sac-carcinoma) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/what-to-know-about-anal-sac-carcinoma)
Anal sac carcinoma is a highly aggressive cancer that develops in the small glandular structures on either side of a dog's anus. These sacs produce a strong-smelling substance that dogs use as a territorial scent marker, among other reasons. Normally, this substance is released during defecation or when a dog is nervous or excited. However, in some cases, these anal sacs can develop cancerous tumors.
Anal sac carcinoma primarily affects older dogs, with an average age of onset around 10 years. Interestingly, there's no significant difference in occurrence between male and female dogs. Certain breeds seem to be predisposed to this condition, including Alaskan Malamutes, Cavalier King Charles Spaniels, Dachshunds, English Cocker Spaniels, English Springer Spaniels, German Shepherds, and Golden Retrievers.
**Treatment Options**
Treatment for anal sac carcinoma usually involves surgery to remove the entire anal sac and the associated tumor. This procedure, known as anal sacculectomy, can be challenging, especially for larger masses, due to the proximity to the rectum. Potential complications include temporary or permanent fecal incontinence, infection, poor wound healing, and anal stricture.
If enlarged lymph nodes are present, they may also need to be surgically removed. This additional procedure carries its own risks, including severe bleeding and nerve damage that could lead to urinary incontinence. The overall complication rate for these surgeries is approximately 10%.
Radiation therapy may be used before, during, or after surgery to reduce the risk of recurrence, especially in cases where complete removal of the tumor isn't possible. It can also be used as a palliative measure when surgery isn't an option. While chemotherapy hasn't been proven to significantly improve survival rates, it may offer some benefits, particularly when combined with radiation therapy.
In canine anal sac tumors, several protein targets have been identified as either mutated or overexpressed across multiple studies. These include HER2 (ERBB2), EGFR, VEGFR, PDGFR, KIT, and components of the PI3K/AKT/mTOR pathway. Palladia, originally approved for mast cell tumors (MCT), has shown benefit for canine apocrine gland anal sac adenocarcinoma (AGASACA) in several veterinary publications. This is likely due to its broad tyrosine kinase inhibition, which affects targets such as KIT, VEGFR, and PDGFR. While inhibitors targeting some of the other common proteins are increasingly being used, many remain in the investigational stage and are not yet widely available for routine clinical use.
**Prognosis**
The outlook for dogs with anal sac carcinoma can vary based on factors such as tumor size, whether the cancer has spread, and the chosen treatment. Some dogs that undergo surgery may survive for more than three years; however, up to 45% of these cases may see a recurrence of cancer at the surgery site. Generally, smaller tumors (less than 2.5 centimeters) and the absence of cancer spread are associated with a better prognosis. Dogs with elevated blood calcium levels often have shorter survival times. Additionally, Palladia has shown benefits in progression-free survival and overall survival in a few publications.
If you notice any unusual symptoms or changes in your dog's behavior, especially related to defecation or the anal area, it's crucial to consult with your veterinarian promptly. Early detection and treatment of anal sac carcinoma can significantly improve your dog's prognosis and quality of life.
For the most accurate prognosis and treatment recommendations for your dog with anal sac carcinoma, consult your veterinarian or a veterinary oncologist. They can provide personalized guidance based on your dog's specific case, considering factors such as cancer stage, grade, tumor location, and concurrent health issues.
## Related Articles
[](https://blog.fidocure.com/fidocure-blog/fidocure-ceo-christina-lopes-to-showcase-worlds-only-portfolio-of-canine-cancer-drugs-at-2024-animal-health-summit)
### [FidoCure CEO Christina Lopes to Showcase World's First Portfolio of Canine Cancer Drugs at 2024 Animal Health Summit](https://blog.fidocure.com/fidocure-blog/fidocure-ceo-christina-lopes-to-showcase-worlds-only-portfolio-of-canine-cancer-drugs-at-2024-animal-health-summit)
FidoCure CEO Christina Lopes will present at the 2024 Animal Health Summit in Kansas City on August 26-27. The summit will showcase emerging companies and foster...
[Christina K. Lopes](https://blog.fidocure.com/fidocure-blog/author/christina-k-lopes)
[Read More](https://blog.fidocure.com/fidocure-blog/fidocure-ceo-christina-lopes-to-showcase-worlds-only-portfolio-of-canine-cancer-drugs-at-2024-animal-health-summit)
[](https://blog.fidocure.com/fidocure-blog/ardent-and-fidocure-announce-groundbreaking-partnership-to-increase-access-to-precision-medicine-treatments-for-pet-cancer)
[Vet](https://blog.fidocure.com/fidocure-blog/tag/vet)
### [Ardent and FidoCure Announce Groundbreaking Partnership](https://blog.fidocure.com/fidocure-blog/ardent-and-fidocure-announce-groundbreaking-partnership-to-increase-access-to-precision-medicine-treatments-for-pet-cancer)
FOR IMMEDIATE RELEASE
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Read More](https://blog.fidocure.com/fidocure-blog/ardent-and-fidocure-announce-groundbreaking-partnership-to-increase-access-to-precision-medicine-treatments-for-pet-cancer)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "FidoCure",
"url" : "https://blog.fidocure.com/fidocure-blog/author/fidocure"
},
"dateModified" : "2024-09-26T13:00:02.254Z",
"datePublished" : "2024-09-26T13:00:00.000Z",
"headline" : "What to Know About Anal Sac Carcinoma",
"image" : [ "https://blog.fidocure.com/hubfs/Blog_AnalSacCarcinoma.png" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/what-to-know-about-anal-sac-carcinoma",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```